REGENXBIO (NASDAQ:RGNX - Get Free Report) released its quarterly earnings results on Wednesday. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.10), Briefing.com reports. REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. The company had revenue of $15.60 million during the quarter, compared to the consensus estimate of $23.52 million. During the same period in the prior year, the company earned ($1.53) earnings per share. The firm's revenue was down 18.3% compared to the same quarter last year.
REGENXBIO Stock Performance
Shares of NASDAQ RGNX traded down $0.99 during trading hours on Thursday, hitting $15.68. 498,751 shares of the stock were exchanged, compared to its average volume of 679,034. The company's fifty day simple moving average is $19.51 and its two-hundred day simple moving average is $17.86. The company has a market cap of $768.99 million, a PE ratio of -2.69 and a beta of 1.38. REGENXBIO has a 1-year low of $11.83 and a 1-year high of $28.80.
Insider Buying and Selling at REGENXBIO
In other REGENXBIO news, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $16.76, for a total value of $251,400.00. Following the transaction, the chief executive officer now owns 408,035 shares in the company, valued at $6,838,666.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Steve Pakola sold 12,878 shares of the company's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $28.36, for a total transaction of $365,220.08. Following the completion of the transaction, the insider now directly owns 107,192 shares in the company, valued at $3,039,965.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kenneth T. Mills sold 15,000 shares of the business's stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $16.76, for a total value of $251,400.00. Following the sale, the chief executive officer now owns 408,035 shares in the company, valued at approximately $6,838,666.60. The disclosure for this sale can be found here. Insiders sold a total of 57,878 shares of company stock worth $1,217,370 over the last three months. Corporate insiders own 13.13% of the company's stock.
Analyst Upgrades and Downgrades
RGNX has been the topic of a number of recent research reports. Robert W. Baird increased their target price on REGENXBIO from $34.00 to $39.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 6th. Wedbush reissued a "neutral" rating and set a $21.00 target price on shares of REGENXBIO in a report on Wednesday, February 28th. Stifel Nicolaus reissued a "buy" rating and issued a $40.00 target price on shares of REGENXBIO in a research report on Friday, April 12th. Barclays raised their price target on shares of REGENXBIO from $45.00 to $55.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. Finally, Royal Bank of Canada raised shares of REGENXBIO from a "sector perform" rating to an "outperform" rating and boosted their price objective for the company from $20.00 to $35.00 in a report on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, REGENXBIO presently has an average rating of "Moderate Buy" and an average price target of $38.45.
Read Our Latest Report on RGNX
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
